182 related articles for article (PubMed ID: 31215145)
1. DACH1 suppresses epithelial to mesenchymal transition (EMT) through Notch1 pathway and reverses progestin resistance in endometrial carcinoma.
Zhou Q; Li W; Kong D; Liu Z; Shi Z; Ma X; Li Y; Jiang J
Cancer Med; 2019 Aug; 8(9):4380-4388. PubMed ID: 31215145
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor signaling pathway involved in progestin-resistance of human endometrial carcinoma: In a mouse model.
Xu Y; Tong J; Ai Z; Wang J; Teng Y
J Obstet Gynaecol Res; 2012 Dec; 38(12):1358-66. PubMed ID: 22612393
[TBL] [Abstract][Full Text] [Related]
3. Roles of SIRT1/FoxO1/SREBP-1 in the development of progestin resistance in endometrial cancer.
Wang Y; Zhang L; Che X; Li W; Liu Z; Jiang J
Arch Gynecol Obstet; 2018 Nov; 298(5):961-969. PubMed ID: 30206735
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer.
Gu C; Zhang Z; Yu Y; Liu Y; Zhao F; Yin L; Feng Y; Chen X
Cancer Sci; 2011 Mar; 102(3):557-64. PubMed ID: 21205080
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin.
Pant A; Lee II; Lu Z; Rueda BR; Schink J; Kim JJ
PLoS One; 2012; 7(7):e41593. PubMed ID: 22911820
[TBL] [Abstract][Full Text] [Related]
6. DACH1 suppresses breast cancer as a negative regulator of CD44.
Xu H; Yu S; Yuan X; Xiong J; Kuang D; Pestell RG; Wu K
Sci Rep; 2017 Jun; 7(1):4361. PubMed ID: 28659634
[TBL] [Abstract][Full Text] [Related]
7. Suppression of the epithelial-mesenchymal transition by SHARP1 is linked to the NOTCH1 signaling pathway in metastasis of endometrial cancer.
Liao Y; He X; Qiu H; Che Q; Wang F; Lu W; Chen Z; Qiu M; Wang J; Wang H; Wan X
BMC Cancer; 2014 Jul; 14():487. PubMed ID: 24997474
[TBL] [Abstract][Full Text] [Related]
8. Overexpressed epidermal growth factor receptor (EGFR)-induced progestin insensitivity in human endometrial carcinoma cells by the EGFR/mitogen-activated protein kinase signaling pathway.
Ai Z; Wang J; Wang Y; Lu L; Tong J; Teng Y
Cancer; 2010 Aug; 116(15):3603-13. PubMed ID: 20564127
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor signaling enhanced by long-term medroxyprogesterone acetate treatment in endometrial carcinoma.
Zhao S; Chen X; Lu X; Yu Y; Feng Y
Gynecol Oncol; 2007 Apr; 105(1):45-54. PubMed ID: 17240435
[TBL] [Abstract][Full Text] [Related]
10. DACH1, a novel target of miR-218, participates in the regulation of cell viability, apoptosis, inflammatory response, and epithelial-mesenchymal transition process in renal tubule cells treated by high-glucose.
Zhang YL; Wang JM; Yin H; Wang SB; He CL; Liu J
Ren Fail; 2020 Nov; 42(1):463-473. PubMed ID: 32408786
[No Abstract] [Full Text] [Related]
11. Notch1 signaling regulates the epithelial-mesenchymal transition and invasion of breast cancer in a Slug-dependent manner.
Shao S; Zhao X; Zhang X; Luo M; Zuo X; Huang S; Wang Y; Gu S; Zhao X
Mol Cancer; 2015 Feb; 14(1):28. PubMed ID: 25645291
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive bioinformatics analysis of acquired progesterone resistance in endometrial cancer cell line.
Li W; Wang S; Qiu C; Liu Z; Zhou Q; Kong D; Ma X; Jiang J
J Transl Med; 2019 Feb; 17(1):58. PubMed ID: 30813939
[TBL] [Abstract][Full Text] [Related]
13. Metformin reverses progestin resistance in endometrial cancer cells by downregulating GloI expression.
Zhang Z; Dong L; Sui L; Yang Y; Liu X; Yu Y; Zhu Y; Feng Y
Int J Gynecol Cancer; 2011 Feb; 21(2):213-21. PubMed ID: 21270604
[TBL] [Abstract][Full Text] [Related]
14. Panobinostat Enhances Growth Suppressive Effects of Progestin on Endometrial Carcinoma by Increasing Progesterone Receptor and Mitogen-Inducible Gene-6.
Ando H; Miyamoto T; Kashima H; Higuchi S; Ida K; Mvunta DH; Shiozawa T
Horm Cancer; 2017 Aug; 8(4):257-267. PubMed ID: 28516379
[TBL] [Abstract][Full Text] [Related]
15. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
[TBL] [Abstract][Full Text] [Related]
16. Organoid modelling identifies that DACH1 functions as a tumour promoter in colorectal cancer by modulating BMP signalling.
Hu X; Zhang L; Li Y; Ma X; Dai W; Gao X; Rao X; Fu G; Wang R; Pan M; Guo Q; Xu X; Zhou Y; Gao J; Zhang Z; Cai S; Peng J; Hua G
EBioMedicine; 2020 Jun; 56():102800. PubMed ID: 32512510
[TBL] [Abstract][Full Text] [Related]
17. Akt regulates progesterone receptor B-dependent transcription and angiogenesis in endometrial cancer cells.
Lee II; Maniar K; Lydon JP; Kim JJ
Oncogene; 2016 Sep; 35(39):5191-201. PubMed ID: 26996671
[TBL] [Abstract][Full Text] [Related]
18. Metformin sensitizes endometrial cancer cells to progestin by targeting TET1 to downregulate glyoxalase I expression.
Jiang Y; Chen X; Wei Y; Feng Y; Zheng W; Zhang Z
Biomed Pharmacother; 2019 May; 113():108712. PubMed ID: 30849641
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of DACH1 activity by short hairpin RNA represses cell proliferation and tumor invasion in pancreatic cancer.
Bu XN; Qiu C; Wang C; Jiang Z
Oncol Rep; 2016 Aug; 36(2):745-54. PubMed ID: 27278537
[TBL] [Abstract][Full Text] [Related]
20. Metformin Increases E-cadherin in Tumors of Diabetic Patients With Endometrial Cancer and Suppresses Epithelial-Mesenchymal Transition in Endometrial Cancer Cell Lines.
Laskov I; Abou-Nader P; Amin O; Philip CA; Beauchamp MC; Yasmeen A; Gotlieb WH
Int J Gynecol Cancer; 2016 Sep; 26(7):1213-21. PubMed ID: 27643646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
